Open AccessRationale for Intensive Statin Treatment in High‐Risk Patients
Author(s) -
Peter H. Jones
Publication year - 2006
Publication title -
preventive cardiology
Language(s) - English
Resource type - Journals
eISSN - 1751-7141
pISSN - 1520-037X
DOI - 10.1111/j.1520-037x.2000.4565.x
Subject(s) - medicine , statin , cholesterol , adverse effect , regimen , incidence (geometry) , clinical trial , national cholesterol education program , surrogate endpoint , clinical endpoint , risk factor , obesity , physics , metabolic syndrome , optics
Intensive lipid‐lowering therapy with 3‐hydroxy‐ 3‐methylglutaryl coenzyme A reductase inhibitors (statins) is now an established regimen for patients at high risk for cardiovascular events, regardless of baseline low‐density lipoprotein cholesterol levels. Treatment with statins to reduce low‐density lipoprotein cholesterol levels significantly below 100 mg/dL has been shown to further reduce the risk of cardiovascular morbidity and mortality in high‐risk patients and has provided the necessary data for an update to the National Cholesterol Education Program's Third Adult Treatment Panel (ATP III) guidelines. Intensive statin therapy is also well tolerated, with no increased risk of noncardiovascular adverse events and a low incidence of clinically significant liver or muscle enzyme abnormalities. Results of recent clinical and surrogate end point trials confirm that intensive lowering of low‐density lipoprotein cholesterol is beneficial and safe in a majority of high‐risk patients.